{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:49:06Z","timestamp":1787280546471,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL088447"],"award-info":[{"award-number":["R01HL088447"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["17POST33680095"],"award-info":[{"award-number":["17POST33680095"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["14PRE18560035"],"award-info":[{"award-number":["14PRE18560035"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["15PRE25670074"],"award-info":[{"award-number":["15PRE25670074"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Receptor interacting protein kinase-1 and -3 (RIP1 and RIP3) are essential mediators of cell death processes and participate in inflammatory responses. Our group recently demonstrated that gene deletion of <jats:italic>Rip3<\/jats:italic> or pharmacological inhibition of RIP1 attenuated pathogenesis of abdominal aortic aneurysm (AAA), a life-threatening degenerative vascular disease characterized by depletion of smooth muscle cells (SMCs), inflammation, negative extracellular matrix remodeling, and progressive expansion of aorta. The goal of this study was to develop drug candidates for AAA and other disease conditions involving cell death and inflammation. We screened 1141 kinase inhibitors for their ability to block necroptosis using the RIP1 inhibitor Necrostatin-1s (Nec-1s) as a selection baseline. Positive compounds were further screened for cytotoxicity and virtual binding to RIP3. A cluster of top hits, represented by GSK2593074A (GSK\u2019074), displayed structural similarity to the established RIP3 inhibitor GSK\u2019843. In multiple cell types including mouse SMCs, fibroblasts (L929), bone marrow derived macrophages (BMDM), and human colon epithelial cells (HT29), GSK\u2019074 inhibited necroptosis with an IC50 of ~3\u2009nM. Furthermore, GSK\u2019074, but not Nec-1s, blocked cytokine production by SMCs. Biochemical analyses identified both RIP1 and RIP3 as the biological targets of GSK\u2019074. Unlike GSK\u2019843 which causes profound apoptosis at high doses (&gt;3\u2009\u00b5M), GSK\u2019074 showed no detectable cytotoxicity even at 20\u2009\u00b5M. Daily intraperitoneal injection of GSK\u2019074 at 0.93\u2009mg\/kg significantly attenuated aortic expansion in two mouse models of AAA (calcium phosphate: DMSO 66.06\u2009\u00b1\u20099.17% vs GSK\u2019074 27.36\u2009\u00b1\u20098.25%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05; Angiotensin II: DMSO 85.39\u2009\u00b1\u200915.76% vs GSK\u2019074 36.28\u2009\u00b1\u20095.76%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Histologically, GSK\u2019074 treatment diminished cell death and macrophage infiltration in aneurysm-prone aortae. Together, our data suggest that GSK\u2019074 represents a new class of necroptosis inhibitors with dual targeting ability to both RIP1 and RIP3. The high potency and minimum cytotoxicity make GSK\u2019074 a desirable drug candidate of pharmacological therapies to attenuate AAA progression and other necroptosis related diseases.<\/jats:p>","DOI":"10.1038\/s41419-019-1468-6","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T14:09:46Z","timestamp":1551881386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Identification of a novel class of RIP1\/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models"],"prefix":"10.1038","volume":"10","author":[{"given":"Ting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner C.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-0086","authenticated-orcid":false,"given":"John B.","family":"Feltenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-1504","authenticated-orcid":false,"given":"Zhengqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Wildman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"1468_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrm3737","volume":"15","author":"T Vanden Berghe","year":"2014","unstructured":"Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H. & Vandenabeele, P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15, 135\u2013147 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1468_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1146\/annurev-biochem-060815-014830","volume":"85","author":"K Newton","year":"2016","unstructured":"Newton, K. & Manning, G. Necroptosis and inflammation. Annu. Rev. Biochem. 85, 743\u2013763 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"1468_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.chom.2012.01.016","volume":"11","author":"JW Upton","year":"2012","unstructured":"Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI\/ZBP1\/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290\u2013297 (2012).","journal-title":"Cell Host Microbe"},{"key":"1468_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ni.3015","volume":"15","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway. Nat. Immunol. 15, 1126\u20131133 (2014).","journal-title":"Nat. Immunol."},{"key":"1468_CR5","doi-asserted-by":"publisher","first-page":"11007","DOI":"10.1073\/pnas.1514730112","volume":"112","author":"L Meng","year":"2015","unstructured":"Meng, L., Jin, W. & Wang, X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc. Natl Acad. Sci. USA 112, 11007\u201311012 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1468_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1074-7613(00)80535-X","volume":"8","author":"MA Kelliher","year":"1998","unstructured":"Kelliher, M. A. et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8, 297\u2013303 (1998).","journal-title":"Immunity"},{"key":"1468_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrm3683","volume":"14","author":"D Ofengeim","year":"2013","unstructured":"Ofengeim, D. & Yuan, J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. Rev. Mol. Cell Biol. 14, 727\u2013736 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1468_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tcb.2015.01.001","volume":"25","author":"K Newton","year":"2015","unstructured":"Newton, K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol. 25, 347\u2013353 (2015).","journal-title":"Trends Cell Biol."},{"key":"1468_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.cell.2014.04.019","volume":"157","author":"JA Rickard","year":"2014","unstructured":"Rickard, J. A. et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175\u20131188 (2014).","journal-title":"Cell"},{"key":"1468_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1128\/MCB.24.4.1464-1469.2004","volume":"24","author":"K Newton","year":"2004","unstructured":"Newton, K., Sun, X. & Dixit, V. M. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 24, 1464\u20131469 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"1468_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/cdd.2016.46","volume":"23","author":"K Newton","year":"2016","unstructured":"Newton, K. et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 23, 1565\u20131576 (2016).","journal-title":"Cell Death Differ."},{"key":"1468_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112\u2013119 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"1468_CR13","doi-asserted-by":"publisher","first-page":"e1600224","DOI":"10.1126\/sciadv.1600224","volume":"2","author":"D Karunakaran","year":"2016","unstructured":"Karunakaran, D. et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci. Adv. 2, e1600224 (2016).","journal-title":"Sci. Adv."},{"key":"1468_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1161\/CIRCRESAHA.116.304899","volume":"116","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ. Res. 116, 600\u2013611 (2015).","journal-title":"Circ. Res."},{"key":"1468_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06088-0","volume":"7","author":"XS Yang","year":"2017","unstructured":"Yang, X. S. et al. Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injury. Sci. Rep. 7, 5818 (2017).","journal-title":"Sci. Rep."},{"key":"1468_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep42159","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Inhibition of receptor-interacting protein kinase 1 with necrostatin-1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model. Sci. Rep. 7, 42159 (2017).","journal-title":"Sci. Rep."},{"key":"1468_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.celrep.2012.12.012","volume":"3","author":"J Lin","year":"2013","unstructured":"Lin, J. et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 3, 200\u2013210 (2013).","journal-title":"Cell Rep."},{"key":"1468_CR18","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1161\/STROKEAHA.117.017702","volume":"48","author":"S Lule","year":"2017","unstructured":"Lule, S. et al. Genetic inhibition of receptor interacting protein kinase-1 reduces cell death and improves functional outcome after intracerebral hemorrhage in mice. Stroke 48, 2549\u20132556 (2017).","journal-title":"Stroke"},{"key":"1468_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/cdd.2016.51","volume":"23","author":"B Shutinoski","year":"2016","unstructured":"Shutinoski, B. et al. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ. 23, 1628\u20131637 (2016).","journal-title":"Cell Death Differ."},{"key":"1468_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.4049\/jimmunol.1400590","volume":"193","author":"A Polykratis","year":"2014","unstructured":"Polykratis, A. et al. Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J. Immunol. 193, 1539\u20131543 (2014).","journal-title":"J. Immunol."},{"key":"1468_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313\u2013321 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"1468_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.tips.2016.12.005","volume":"38","author":"KW Wegner","year":"2017","unstructured":"Wegner, K. W., Saleh, D. & Degterev, A. Complex pathologic roles of RIPK1 and RIPK3: moving beyond necroptosis. Trends Pharmacol. Sci. 38, 202\u2013225 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"1468_CR23","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.celrep.2015.02.051","volume":"10","author":"D Ofengeim","year":"2015","unstructured":"Ofengeim, D. et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836\u20131849 (2015).","journal-title":"Cell Rep."},{"key":"1468_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrd.2015.6","volume":"15","author":"M Conrad","year":"2016","unstructured":"Conrad, M., Angeli, J. P., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 15, 348\u2013366 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1468_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2014.10.021","volume":"56","author":"P Mandal","year":"2014","unstructured":"Mandal, P. et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol. Cell 56, 481\u2013495 (2014).","journal-title":"Mol. Cell"},{"key":"1468_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cell.2012.06.019","volume":"150","author":"J Li","year":"2012","unstructured":"Li, J. et al. The RIP1\/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150, 339\u2013350 (2012).","journal-title":"Cell"},{"key":"1468_CR27","doi-asserted-by":"publisher","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","volume":"288","author":"WJ Kaiser","year":"2013","unstructured":"Kaiser, W. J. et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288, 31268\u201331279 (2013).","journal-title":"J. Biol. Chem."},{"key":"1468_CR28","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.1021\/jm300713s","volume":"55","author":"JM Axten","year":"2012","unstructured":"Axten, J. M. et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 55, 7193\u20137207 (2012).","journal-title":"J. Med. Chem."},{"key":"1468_CR29","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1016\/j.bmcl.2005.07.077","volume":"15","author":"X Teng","year":"2005","unstructured":"Teng, X. et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg. Med. Chem. Lett. 15, 5039\u20135044 (2005).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1468_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jvs.2012.01.038","volume":"56","author":"D Yamanouchi","year":"2012","unstructured":"Yamanouchi, D. et al. Accelerated aneurysmal dilation associated with apoptosis and inflammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. J. Vasc. Surg. 56, 455\u2013461 (2012).","journal-title":"J. Vasc. Surg."},{"key":"1468_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.130","volume":"6","author":"A Fauster","year":"2015","unstructured":"Fauster, A. et al. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 6, e1767 (2015).","journal-title":"Cell Death Dis."},{"key":"1468_CR32","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.celrep.2015.02.052","volume":"10","author":"M Najjar","year":"2015","unstructured":"Najjar, M. et al. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 10, 1850\u20131860 (2015).","journal-title":"Cell Rep."},{"key":"1468_CR33","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","volume":"59","author":"PA Harris","year":"2016","unstructured":"Harris, P. A. et al. DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J. Med. Chem. 59, 2163\u20132178 (2016).","journal-title":"J. Med. Chem."},{"key":"1468_CR34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","volume":"60","author":"PA Harris","year":"2017","unstructured":"Harris, P. A. et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J. Med. Chem. 60, 1247\u20131261 (2017).","journal-title":"J. Med. Chem."},{"key":"1468_CR35","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/cddiscovery.2015.9","volume":"1","author":"SB Berger","year":"2015","unstructured":"Berger, S. B. et al. Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 1, 15009 (2015).","journal-title":"Cell Death Discov."},{"key":"1468_CR36","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/ml400382p","volume":"4","author":"PA Harris","year":"2013","unstructured":"Harris, P. A. et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med. Chem. Lett. 4, 1238\u20131243 (2013).","journal-title":"ACS Med. Chem. Lett."},{"key":"1468_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/cdd.2015.70","volume":"23","author":"DA Rodriguez","year":"2016","unstructured":"Rodriguez, D. A. et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 23, 76\u201388 (2016).","journal-title":"Cell Death Differ."},{"key":"1468_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.241","volume":"5","author":"JX Li","year":"2014","unstructured":"Li, J. X. et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 5, e1278 (2014).","journal-title":"Cell Death Dis."},{"key":"1468_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/1673-5374.226394","volume":"13","author":"SA Cruz","year":"2018","unstructured":"Cruz, S. A., Qin, Z., Stewart, A. F. R. & Chen, H. H. Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury. Neural Regen. Res. 13, 252\u2013256 (2018).","journal-title":"Neural Regen. Res."},{"key":"1468_CR40","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.chembiol.2013.05.005","volume":"20","author":"SB Hari","year":"2013","unstructured":"Hari, S. B., Merritt, E. A. & Maly, D. J. Sequence determinants of a specific inactive protein kinase conformation. Chem. Biol. 20, 806\u2013815 (2013).","journal-title":"Chem. Biol."},{"key":"1468_CR41","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1021\/jm8010299","volume":"51","author":"I Kufareva","year":"2008","unstructured":"Kufareva, I. & Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 51, 7921\u20137932 (2008).","journal-title":"J. Med. Chem."},{"key":"1468_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1566524016666160523143937","volume":"16","author":"W Rozpedek","year":"2016","unstructured":"Rozpedek, W. et al. The role of the PERK\/eIF2alpha\/ATF4\/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Curr. Mol. Med. 16, 533\u2013544 (2016).","journal-title":"Curr. Mol. Med."},{"key":"1468_CR43","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/cdd.2017.58","volume":"24","author":"D Rojas-Rivera","year":"2017","unstructured":"Rojas-Rivera, D. et al. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 24, 1100\u20131110 (2017).","journal-title":"Cell Death Differ."},{"key":"1468_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.4017","volume":"22","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat. Med. 22, 175\u2013182 (2016).","journal-title":"Nat. Med."},{"key":"1468_CR45","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/cdd.2014.77","volume":"21","author":"XN Wu","year":"2014","unstructured":"Wu, X. N. et al. Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis. Cell Death Differ. 21, 1709\u20131720 (2014).","journal-title":"Cell Death Differ."},{"key":"1468_CR46","doi-asserted-by":"publisher","first-page":"e92053","DOI":"10.1371\/journal.pone.0092053","volume":"9","author":"Q Wang","year":"2014","unstructured":"Wang, Q. et al. Monocyte chemoattractant protein-1 (MCP-1) regulates macrophage cytotoxicity in abdominal aortic aneurysm. PLoS One 9, e92053 (2014).","journal-title":"PLoS One"},{"key":"1468_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1161\/ATVBAHA.109.200527","volume":"30","author":"D Yamanouchi","year":"2010","unstructured":"Yamanouchi, D. et al. Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 30, 702\u2013707 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1468_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/CIRCRESAHA.117.305262","volume":"117","author":"Z Liu","year":"2015","unstructured":"Liu, Z. et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ. Res. 117, 129\u2013141 (2015).","journal-title":"Circ. Res."},{"key":"1468_CR49","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1172\/JCI7818","volume":"105","author":"A Daugherty","year":"2000","unstructured":"Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605\u20131612 (2000).","journal-title":"J. Clin. Invest."},{"key":"1468_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2011.02.023","volume":"145","author":"S Biton","year":"2011","unstructured":"Biton, S. & Ashkenazi, A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 145, 92\u2013103 (2011).","journal-title":"Cell"},{"key":"1468_CR51","doi-asserted-by":"publisher","first-page":"e0181585","DOI":"10.1371\/journal.pone.0181585","volume":"12","author":"DH Drewry","year":"2017","unstructured":"Drewry, D. H. et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS One 12, e0181585 (2017).","journal-title":"PLoS One"},{"key":"1468_CR52","doi-asserted-by":"publisher","first-page":"e57888","DOI":"10.1371\/journal.pone.0057888","volume":"8","author":"P Dranchak","year":"2013","unstructured":"Dranchak, P. et al. Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays. PLoS One 8, e57888 (2013).","journal-title":"PLoS One"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1468-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:38:59Z","timestamp":1671208739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1468-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"226"}}